Stocks in play: Revive Therapeutics Ltd
Provides an update on the Company’s U.S. Food & Drug Administration Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19. Revive Therapeutics Ltd shares C.RVV are trading up $0.05 at $0.43.
Innovative Food Stocks Responding to Conflict-, and Drought-Driven Food Supply Shocks
Crypto Miners Finding Success While Shifting Towards Environmentally Sustainable Operations
New Approaches Towards Immunotherapy Give Hope in Fight Against Solid Tumors
As a Major Social Media Shuffle Looms, Uptake and Value of Dogecoin (DOGE) Surges
New Regions Being Developed to Produce More Oil Amid Government’s Calls for More Output